Olmesartan-medoxomil/azelnidipine
- PDF / 169,368 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 62 Downloads / 149 Views
1 S
Enteropathy: case report A 75-year-old woman developed enteropathy during treatment with olmesartan medoxomil/azelnidipine for hypertension. The woman, who had a history of hypertension, received olmesartan-medoxomil/azelnidipine [olmesartan/azelnidipine ] tablets for 1.5 years [dosage and route not stated]. She presented to a hospital with watery diarrhoea and 10kg weight loss. CT scan revealed small intestine dilation and increased wall thickness. Esophagogastroduodenoscopy revealed granular alteration in the descending duodenum. Magnifying endoscopy with narrow-band imaging and biopsy revealed villous atrophy. Olmesartan medoxomil/ azelnidipine associated sprue-like enteropathy was suspected. The woman’s treatment with olmesartan-medoxomil/azelnidipine was stopped. The diarrhoea improved within a week and she gained 8kg weight within 2 months. Azelnidipine was restarted with no diarrhoeal reoccurrence. CT scan showed colon dilation and biopsies showed a few intraepithelial lymphocytes, but the colonoscopic findings were normal. A diagnosis of olmesartanmedoxomil/azelnidipine associated enteropathy was made. Sasaki S, et al. Olmesartan-associated enteropathy mimics endoscopic findings of celiac disease. Internal Medicine 59: 1777-1778, No. 14, 15 Jul 2020. Available from: URL: 803504441 http://doi.org/10.2169/internalmedicine.4336-19
0114-9954/20/1824-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 3 Oct 2020 No. 1824
Data Loading...